nach oben

Neuropsychology Review

Erschienen in:

01.09.2009 | Review

Pharmacological Cognitive Enhancement in Schizophrenia

verfasst von: Philip D. Harvey

Erschienen in: Neuropsychology Review | Ausgabe 3/2009

Einloggen, um Zugang zu erhalten

Abstract

Cognitive impairments in schizophrenia are common and severe. These impairments are also related to functional disability in schizophrenia. As a result, efforts are underway to enhance cognition in schizophrenia through a variety of pharmacological mechanisms. As part of this effort, a designated research design has been developed for this process, through an extensive consensus and validation effort. This paper reviews the methods for pharmacological cognitive enhancement, as well as previous results of efforts in the pharmacological domains. These domains include cholinergic, noradrenergic, serotonergic, glutamatergic, and GABA-ergic mechanisms. While previous results have not been particularly encouraging, there are many challenges that need to be overcome and many of the reasons for past failures may be due to resolvable issues. It is likely that this will be an area of research that will be developing extensively over the next decade and expanding to other conditions as well.

Akbarian, S., Kim, J. J., Potkin, S. G., Hetrick, W. P., Bunney, W. E., Jr., & Jones, E. G. (1996). Maldistribution of interstitial neurons in the prefrontal white matter of brains of schizophrenic patients. Archives of General Psychiatry, 53, 425–436.PubMed

Anand, A., Charney, D. S., Oren, D. A., Berman, R. M., Hu, X. S., Cappiello, A., et al. (2000). Attenuation of the neuropsychiatric effects of ketamine with lamotrigine. Archives of General Psychiatry, 57, 270–276.PubMedCrossRef

Angrist, B., Rotrosen, J., & Gershon, S. (1980). Differential effects of amphetamine and neuroleptics on negative vs. positive symptoms in schizophrenia. Psychopharmacology (Berl), 72(1), 17–9.CrossRef

Apud, J. A., Mattay, V., Chen, J., Kolachana, B. S., Callicott, J. H., Rasetti, R., et al. (2007). Tolcapone improves cognition and cortical information processing in normal human subjects. Neuropsychopharmacology, 32, 1011–20.PubMedCrossRef

Arnsten, A. F. (2004). Adrenergic targets for the treatment of cognitive deficits in schizophrenia. Psychopharmacology, 174, 25–31.PubMedCrossRef

Arnsten, A. F., Cai, J. X., Murphy, B. L., & Goldman-Rakic, P. S. (1994). Dopamine D1 receptor mechanisms in the cognitive performance of young adult and aged monkeys. Psychopharmacology, 116, 143–151.PubMedCrossRef

Arnsten, A. F. T., Cai, J. X., & Goldman-Rakic, P. S. (1988). The alpha-2adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects: Evidence for alpha-2 receptor subtypes. Journal of Neuroscience, 8, 4287–4297.PubMed

Barch, D. M., & Carter, C. S. (2005). Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers. Schizophrenia Research, 77, 43–58.PubMedCrossRef

Bell, M. D., Zito, W., Greig, T., & Wexler, B. E. (2008). Neurocognitive enhancement therapy with vocational services: work outcomes at two-year follow-up. Schizophrenia Research, 105, 18–29.PubMedCrossRef

Buchanan, R. W., Davis, M., Goff, D., Green, M. F., Keefe, R. S. E., Leon, A. C., et al. (2005). A summary of the FDA-NIMHMATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophrenia Bulletin, 31, 5–19.PubMedCrossRef

Buchanan, R. W., Conley, R. R., Dickinson, D., Ball, M. P., Feldman, S., Gold, J. M., et al. (2007). Galantamine for the Treatment of Cognitive Impairments in People With Schizophrenia. American Journal of Psychiatry, 165, 82–89.PubMedCrossRef

Buchanan, R. W., Javitt, D. C., Marder, S. R., Schooler, N. R., Gold, J. M., McMahon, R. P., et al. (2007). The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): The Efficacy of Glutamatergic Agents for Negative Symptoms and Cognitive Impairments. American Journal of Psychiatry, 164, 1593–1602.PubMedCrossRef

Cahn, W., Rais, M., Stigter, F. P., van Haren, N. E., Caspers, E., Hulshoff Pol, H. E., et al. (2009). Psychosis and brain volume changes during the first 5 years of schizophrenia. European Neuropsychopharmacology, 19, 147–151.PubMedCrossRef

DeLisi, L. E., Szulc, K. U., Bertisch, H. C., Majcher, M., & Brown, K. (2006). Understanding structural brain changes in schizophrenia. Dialogues in Clinical Neuroscience, 8, 71–78.PubMed

Egan, M. F., Goldberg, T. E., Kolachana, B. S., Callicott, J. H., Mazzanti, C. M., Straub, R. E., et al. (2001). Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proceedings of the National Academy of Sciences, 98, 6917–22.CrossRef

Emre, M., Aarsland, D., Albanese, A., et al. (2004). Rivastigmine for dementia associated with Parkinson's disease. New England Journal of Medicine, 351, 2509–2518.PubMedCrossRef

Freedman, R., Olincy, A., Buchanan, R. W., Harris, J. G., Gold, J. M., Johnson, L., et al. (2008). Initial Phase 2 Trial of a Nicotinic Agonist in Schizophrenia. American Journal of Psychiatry, 165, 1040–1047.PubMedCrossRef

Friedman, J. I. (2004). Cholinergic targets for cognitive enhancement in schizophrenia: Focus on cholinesterase inhibitors and muscarinic agonists. Psychopharmacology (Berl), 174, 45–53.CrossRef

Friedman, J. I., Adler, D. N., Howanitz, E., Harvey, P. D., Brenner, G., Temporini, H., et al. (2002). A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biological Psychiatry, 51, 349–357.PubMedCrossRef

Friedman, J. I., Adler, D. N., Temporini, H. D., Kemether, E., Harvey, P. D., White, L., et al. (2001). Guanfacine treatment of cognitive impairment in schizophrenia. Neuropsychopharmacolog, 25, 402–409.CrossRef

Friedman, J. I., Carpenter, D., Lu, J., Fan, J., Tang, C. Y., White, L., et al. (2008). A Pilot Study of Adjunctive Atomoxetine Treatment to Second-Generation Antipsychotics for Cognitive Impairment in Schizophrenia. Journal of Clinical Psychopharmacology, 28, 59–63.PubMedCrossRef

Geyer, M. A., & Tamminga, C. A. (2004). Measurement and treatment research to improve cognition in schizophrenia: Neuropharmacological aspects. Psychopharmacology, 174, 1–2.CrossRef

Giakoumaki, S. G., Roussos, P., & Bitsios, P. (2008). Improvement of prepulse inhibition and executive function by the COMT inhibitor tolcapone depends on COMT Val158Met polymorphism. Neuropsychopharmacology, 33, 3058–3068.PubMedCrossRef

Goff, D. C., Keefe, R. S. E., Citrome, L., Davy, D., Krystal, J. H., Large, C., et al. (2007). Lamotrigine as Add-On Therapy in Schizophrenia Results of 2 Placebo-Controlled Trials. Journal of Clinical Psychopharmacology, 27, 582–589.PubMedCrossRef

Goff, D. C. Lamberti, JS, L. A. C., Green, M. F., Miller, A. L., Patel, J., et al. (2008). A Placebo-Controlled Add-On Trial of the Ampakine, CX516, for Cognitive Deficits in Schizophrenia. Neuropsychopharmacology, 33, 465–472.PubMedCrossRef

Green, M. F., Nuechterlein, K. H., Kern, R. S., Baade, L. E., Fenton, W. S., Gold, J. M., et al. (2008). Functional co-primary measures for clinical trials in schizophrenia: Results from the MATRICS psychometric and standardization study. American Journal of Psychiatry, 165, 221–228.PubMedCrossRef

Harvey, P. D., & Cornblatt, B. A. (2008). Pharmacological cognitive enhancement in schizophrenia: An idea whose method has come. American Journal of Psychiatry, 165, 163–165.PubMedCrossRef

Harvey, P. D., & Keefe, R. S. E. (2001). Interpreting studies of cognitive change in schizophrenia with novel antipsychotic treatment. American Journal of Psychiatry, 158, 176–184.PubMedCrossRef

Heinrichs, R. W. (2005). The primacy of cognition in schizophrenia. American Psychologist, 60, 229–242.PubMedCrossRef

Hunt, R. D., Arnsten, A. F. T., & Asbell, M. D. (1995). An open trial of guanfacine in the treatment of attention deficit hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 34, 50–54.PubMedCrossRef

Kahn, A. (2008). Current evidence for aripiprazole as augmentation therapy in major depressive disorder. Expert Reviews of Neurotherapy, 8, 1435–47.CrossRef

Keefe, R. S. E., Malhotra, A. K., Meltzer, H. Y., Kane, J. M., Buchanan, R. W., Murth, A., et al. (2008). Efficacy and Safety of Donepezil in Patients with Schizophrenia or Schizoaffective Disorder: Significant Placebo/Practice Effects in a 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Neuropsychopharmacology, 33, 1217–28.PubMedCrossRef

Kern, R. S., Nuechterlein, K. H., Green, M. F., Baade, L. E., Fenton, W. S., et al. (2008). The MATRICS Consensus Cognitive Battery: Part 2. co-norming and standardization. American Journal of Psychiatry, 165, 214–220.PubMedCrossRef

Kumari, V., Aasen, I., Ffytche, D., Williams, S. C., & Sharma, T. (2006). Neural correlates of adjunctive rivastigmine treatment to antipsychotics in schizophrenia: A randomized, placebo-controlled, double-blind fMRI study. Neuroimage, 29, 545–56.PubMedCrossRef

Laruelle, M., Abi-Dargham, A., Gil, R., Kegeles, L., & Innis, R. (1999). Increased dopamine transmission in schizophrenia: relationship to illness phases. Biological Psychiatry, 46, 56–72.PubMedCrossRef

Lewis, D. A., Cho, R. Y., Carter, C. S., Eklund, K., Forster, S., Kelly, M. A., et al. (2008). Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia. American Journal of Psychiatry, 165, 1585–1593.PubMedCrossRef

Lewis, D. A., Volk, D. W., & Hashimoto, T. (2004). Selective alterations in prefrontal cortical GABA neurotransmission in schizophrenia: a novel target for the treatment of working memory dysfunction. Psychopharmacology, 174, 143–150.PubMedCrossRef

Levy, D. L., Smith, M., Robinson, D., Jody, D., Lerner, G., Alvir, J., et al. (1993). Methylphenidate increases thought disorder in recent onset schizophrenics, but not in normal controls. Biological Psychiatry, 34, 507–514.PubMedCrossRef

Lim, K. O., Hedehus, M., Moseley, M., deCrespigny, A., Sullivan, E. V., & Pfefferbaum, A. (1999). Compromised white matter tract integrity in schizophrenia inferred from diffusion tensor imaging. Archives of General Psychiatry, 56, 367–374.PubMedCrossRef

Lindenmayer, J. P., McGurk, S. R., Mueser, K. T., Khan, A., Wance, D., Hoffman, L., et al. (2008). A randomized controlled trial of cognitive remediation among inpatients with persistent mental illness. Psychiatric Services, 59, 241–247.PubMedCrossRef

Marder, S. R., & Fenton, W. (2004). Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia. Schizophrenia Research, 72, 5–9.PubMedCrossRef

Menzies, L., Ooi, C., Kamath, S., Suckling, J., McKenna, P., Fletcher, P., et al. (2007). Effects of gamma-aminobutyric acidmodulating drugs on working memory and brain function in patients with schizophrenia. Archives of General Psychiatry, 64, 156–167.PubMedCrossRef

McClure, M. M., Barch, D. M., Romero, M. J., Minzenberg, M. J., Triebwasser, J., Harvey, P. D., et al. (2007). The Effects of Guanfacine on Context Processing Abnormalities in Schizotypal Personality Disorder. Biological Psychiatry, 61, 1157–1160.PubMedCrossRef

Minzenberg, M. J., & Carter, C. S. (2008). Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology, 33, 1477–1502.PubMedCrossRef

Moghaddam, B. (2004). Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia. Psychopharmacology, 174, 39–44.PubMedCrossRef

McGurk, S. R., Mueser, K. T., & Pascaris, A. (2005). Cognitive training and supported employment for persons with severe mental illness: one-year results from a randomized controlled trial. Schizophrenia Bulletin, 31, 898–909.PubMedCrossRef

McGurk, S. R., Mueser, K. T., Feldman, K., Wolfe, R., & Pascaris, A. (2007). Cognitive Training for Supported Employment: 2–3 Year Outcomes of a Randomized Controlled Trial. American Journal of Psychiatry, 164, 437–441.PubMedCrossRef

Morein-Zamir, S., Turner, D. C., & Sahakian, B. J. (2007). A review of the effects of modafinil on cognition in schizophrenia. Schizophrenia Bulletin, 33, 1298–1306.PubMedCrossRef

Nuechterlein, K. H., Green, M. F., Kern, R. S., Baade, L. E., Barch, D., Cohen, J., et al. (2008). The MATRICS Consensus Cognitive Battery: Part 1. Test selection, reliability, and validity. American Journal of Psychiatry, 165, 203–213.PubMedCrossRef

Patterson, T. L., Mausbach, B. T., McKibbin, C., et al. (2006). Functional adaptation skills training (FAST): a randomized trial of psychosocial intervention for middle-aged and older patients with chronic psychotic disorders. Schizophrenia Research, 86, 291–299.PubMedCrossRef

Rogers, S. L., Doody, R. S., Mohs, R. C., & Friedhoff, L. T. (1998). Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Archives of Internal Medicine, 158, 1021–1031.PubMedCrossRef

Sharma, T. S., Reed, C., Aasen, I., & Kumari, V. (2006). Cognitive effects of adjunctive 24- week rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind investigation. Schizophrenia Research, 85, 73–83.PubMedCrossRef

Sumiyoshi, T., Matsui, M., Nohara, S., Yamashita, I., Kurachi, M., Sumiyoshi, C., et al. (2001). Enhancement of Cognitive Performance in Schizophrenia by Addition of Tandospirone to Neuroleptic Treatment. American Journal of Psychiatry, 158, 1722–1725.PubMedCrossRef

Sumiyoshi, T., Park, S., Jayathilake, K., Roy, A., Ertugrul, A., & Meltzer, H. Y. (2007). Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: A randomized, double-blind, placebo-controlled study. Schizophrenia Research, 95, 158–168.PubMedCrossRef

Vitiello, B., Martin, A., Hill, J., Mack, C., Molchan, S. E., Martinez, R., et al. (1997). Cognitive and behavioral effects of cholinergic, dopaminergic, and serotonergic blockade in humans. Neuropharmacology, 16, 15–24.

Wexler, B. E., & Bell, M. D. (2005). Cognitive remediation and vocational rehabilitation for schizophrenia. Schizophrenia Bulletin, 31, 931–941.PubMedCrossRef

Woodward, N. D., Purdon, S. E., Meltzer, H. Y., et al. (2005). A meta-analysis of cognitive change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. International Journal of Neuropsychopharmacology, 8, 457–472.PubMedCrossRef

Zoccali, R., Muscatello, M. R., Bruno, A., Cambria, R., Micò, U., Spina, E., et al. (2007). The effect of lamotrigine augmentation of clozapine in a sample of treatment-resistant schizophrenic patients: a double-blind, placebo-controlled study. Schizophrenia Research, 93, 109–116.PubMedCrossRef

Titel: Pharmacological Cognitive Enhancement in Schizophrenia
verfasst von: Philip D. Harvey
Publikationsdatum: 01.09.2009
Verlag: Springer US
Erschienen in: Neuropsychology Review / Ausgabe 3/2009
Print ISSN: 1040-7308
Elektronische ISSN: 1573-6660
DOI: https://doi.org/10.1007/s11065-009-9103-4

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Bluttest erkennt Parkinson schon zehn Jahre vor der Diagnose

10.05.2024 Parkinson-Krankheit Nachrichten

Ein Bluttest kann abnorm aggregiertes Alpha-Synuclein bei einigen Menschen schon zehn Jahre vor Beginn der motorischen Parkinsonsymptome nachweisen. Mit einem solchen Test lassen sich möglicherweise Prodromalstadien erfassen und die Betroffenen früher behandeln.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2009

Episodic Memory in Schizophrenia

Neurobiological Markers of Illness Onset in Psychosis and Schizophrenia: The Search for a Moving Target

Cognitive Remediation in Schizophrenia

How the Conflict between American Psychiatry and Neurology Delayed the Appreciation of Cognitive Dysfunction in Multiple Sclerosis

The Neuropsychology of Schizophrenia Circa 2009